Atara Biotherapeutics (FRA:AT20) Cyclically Adjusted Book per Share: €98.36 (As of Mar. 2026)


FRA:AT20 Atara Biotherapeutics Inc FRA:AT20
29 GF Score
Price €10.00
GF Value €1.32
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Cyclically Adjusted Book per Share?

Atara Biotherapeutics FRA:AT20 +2.56% 29 Cyclically Adjusted Book per Share is €98.36 as of Mar. 2026. GuruFocus rates FRA:AT20 with a GF Score™ of 29/100 and a GF Value™ of €1.32 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Atara Biotherapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €-3.792. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €98.36 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Atara Biotherapeutics's average Cyclically Adjusted Book Growth Rate was -19.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Atara Biotherapeutics was -7.90% per year. The lowest was -7.90% per year. And the median was -7.90% per year.

As of today (2026-07-05), Atara Biotherapeutics's current stock price is €10.00. Atara Biotherapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €98.36. Atara Biotherapeutics's Cyclically Adjusted PB Ratio of today is 0.10.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Atara Biotherapeutics was 0.78. The lowest was 0.03. And the median was 0.09.


Atara Biotherapeutics  (FRA:AT20) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Atara Biotherapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=10.00/98.36
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Atara Biotherapeutics was 0.78. The lowest was 0.03. And the median was 0.09.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Atara Biotherapeutics Cyclically Adjusted Book per Share Related Terms


Atara Biotherapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Cyclically Adjusted Book per Share Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 153.22 153.76 110.47 108.62

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.92 131.01 114.80 108.62 98.36

FRA:AT20 vs ANIX, BMEA, PMN: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:AT20
29GF Score
Atara Biotherapeutics Inc FRA:AT20
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Atara Biotherapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-3.792/330.2130*330.2130
=-3.792

Current CPI (Mar. 2026) = 330.2130.

Atara Biotherapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 225.016 241.018 308.289
201609 208.622 241.428 285.343
201612 207.901 241.432 284.352
201703 187.268 243.801 253.643
201706 164.564 244.955 221.841
201709 141.174 246.819 188.873
201712 122.290 246.524 163.805
201803 202.835 249.554 268.394
201806 213.645 251.989 279.966
201809 189.166 252.439 247.446
201812 162.054 251.233 212.999
201903 135.681 254.202 176.252
201906 109.636 256.143 141.340
201909 133.554 256.759 171.761
201912 115.186 256.974 148.015
202003 97.033 258.115 124.137
202006 113.876 257.797 145.864
202009 97.278 260.280 123.415
202012 113.956 260.474 144.466
202103 99.670 264.877 124.255
202106 81.173 271.696 98.656
202109 74.574 274.310 89.772
202112 67.482 278.802 79.926
202203 54.518 287.504 62.617
202206 64.540 296.311 71.924
202209 49.798 296.808 55.403
202212 31.157 296.797 34.665
202303 15.710 301.836 17.187
202306 1.701 305.109 1.841
202309 -11.684 307.789 -12.535
202312 -21.370 306.746 -23.005
202403 -18.791 312.332 -19.867
202406 -21.002 314.175 -22.074
202409 -14.212 315.301 -14.884
202412 -15.857 315.605 -16.591
202503 -8.599 319.799 -8.879
202506 -4.354 322.561 -4.457
202509 -4.329 324.800 -4.401
202512 -4.489 324.054 -4.574
202603 -3.792 330.213 -3.792

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €98.36 mean?
Atara Biotherapeutics (FRA:AT20) has a Cyclically Adjusted Book per Share of €98.36 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Cyclically Adjusted Book per Share too high?
Atara Biotherapeutics' current Cyclically Adjusted Book per Share is €98.36. Overall, Atara Biotherapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Cyclically Adjusted Book per Share compare to ANIX and BMEA?
Atara Biotherapeutics' Cyclically Adjusted Book per Share of €98.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Cyclically Adjusted Book per Share is €98.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (FRA:AT20) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.32, compared to a current price of €10.00 — trading 657.6% above its estimated fair value. The current Cyclically Adjusted Book per Share is €98.36. Atara Biotherapeutics' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Atara Biotherapeutics (FRA:AT20), the current Cyclically Adjusted Book per Share is €98.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (FRA:AT20) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of €10.00 is trading 657.6% above its estimated GF Value™ of €1.32. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for FRA:AT20:

  • Cyclically Adjusted Book per Share: €98.36
  • GF Value™: €1.32 vs. price of €10.00 (657.6% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the FRA:AT20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atara Biotherapeutics Business Description

Other Exchanges ATRA:USA0HIY:UK
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
29GF Score

Get the complete analysis for FRA:AT20

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.00
Price
€1.32
GF Value